Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Sep 11, 2024
- Accession no.
- 0001447362-24-000148
- Filed
- Sep 11, 2024
- Trade date
- Sep 9, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions. Open-market sales total $76.2K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2024 | Common Stock | SSaleDisposed | −996 | $29.46F2 | −$29,342.16 | 98,576 | Direct | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −512 | $29.46F2 | −$15,083.52 | 80,178 | Indirect | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −478 | $29.46F2 | −$14,081.88 | 69,109 | Indirect | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −150 | $29.46F2 | −$4,419 | 7,810 | Indirect | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −150 | $29.46F2 | −$4,419 | 7,806 | Indirect | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −150 | $29.46F2 | −$4,419 | 7,806 | Indirect | |
| Sep 9, 2024 | Common Stock | SSaleDisposed | −150 | $29.46F2 | −$4,419 | 7,806 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $29.190 to $29.705, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.